Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMFQ320)

• Drug Name: Ipratropium Drug Info
• Synonyms: Aerodose; Atrovent; Atrovent Hfa; Ipatropium Bromide; Ipratropium bromide; X8M; Apo-Ipravent; Apovent (TN); Atrovent (TN); Kendral-Ipratropium; [(5R)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(1R,5R)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(1R,5S)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(1R,5S)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] (2R)-3-hydroxy-2-phenylpropanoate; (3-endo,8-syn)-3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo(3.2.1)octane; (3-endo,8-syn)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-isopropyl-8-methyl-8-azoniabicyclo[3.2.1]octane; (8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl) 3-hydroxy-2-phenylpropanoate; 3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-(propan-2-yl)-8-azoniabicyclo[3.2.1]octane
• Therapeutic Class: Bronchodilator Agents
• Cross-matching ID:
  PubChem CID: 657309
  ChEBI ID: CHEMBL1740585
  CAS Number: CAS 60205-81-4
  TTD Drug ID: D0S0AS
  VARIDT Drug ID: DR00277

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Propanoate metabolism	1.83	1.21e-1	30/34 (88.24%)	DLD;ALDH6A1;DBT;...
Nitrogen metabolism	1.65	4.74e-1	16/17 (94.12%)	CA2;CA12;CPS1;...
Mineral absorption	1.62	4.20e-1	48/60 (80%)	SLC39A4;MT1F;MT1E;...
Oxidative phosphorylation	1.58	4.36e-1	93/133 (69.92%)	COX4I1;CYC1;NDUFV2;...
Adherens junction	1.57	3.75e-1	63/71 (88.73%)	SRC;CDC42;ACTN1;...
Protein export	1.56	3.26e-1	17/23 (73.91%)	SEC62;OXA1L;SRP72;...
Non-homologous end-joining	1.56	2.81e-1	11/13 (84.62%)	XRCC5;DNTT;LIG4;...
Spliceosome	1.56	2.50e-1	101/150 (67.33%)	PRPF4;SRSF1;LSM3;...
Arginine and proline metabolism	1.56	2.24e-1	39/50 (78%)	AOC1;GATM;OAT;...
Regulation of actin cytoskeleton	1.56	2.03e-1	185/218 (84.86%)	SRC;CDC42;ITGA6;...
Thiamine metabolism	1.50	2.85e-1	12/15 (80%)	AK4;ACP1;AK2;...
Homologous recombination	1.48	3.05e-1	35/41 (85.37%)	SSBP1;RAD54B;RBBP8;...
Citrate cycle (TCA cycle)	1.48	2.85e-1	30/30 (100%)	DLD;DLST;IDH2;...
Thermogenesis	1.46	3.03e-1	173/232 (74.57%)	MAPK13;GNAS;COX4I1;...
Oocyte meiosis	1.46	2.93e-1	90/129 (69.77%)	MAPK13;ITPR1;CCNB2;...
Neutrophil extracellular trap formation	1.43	3.35e-1	101/189 (53.44%)	SRC;CTSG;ELANE;...
DNA replication	1.43	3.25e-1	34/36 (94.44%)	SSBP1;POLE3;RNASEH1;...
Diabetic cardiomyopathy	1.41	3.41e-1	162/203 (79.8%)	MAPK13;AGT;PRKCA;...
Leukocyte transendothelial migration	1.40	3.50e-1	90/114 (78.95%)	MAPK13;CDC42;CXCL12;...
Fat digestion and absorption	1.40	3.53e-1	35/43 (81.4%)	APOA1;ABCA1;MTTP;...
Parkinson disease	1.39	3.55e-1	176/249 (70.68%)	ITPR1;GNAS;KIF5C;...
Platelet activation	1.38	3.52e-1	106/124 (85.48%)	SRC;MAPK13;F2R;...
Inflammatory mediator regulation of TRP channels	1.38	3.38e-1	82/98 (83.67%)	SRC;MAPK13;ITPR1;...
Glycine, serine and threonine metabolism	1.35	4.17e-1	31/40 (77.5%)	GATM;DLD;GLDC;...
Glycosylphosphatidylinositol (GPI)-anchor biosynthesis	1.33	4.52e-1	20/26 (76.92%)	PIGP;PIGB;PIGC;...
Type I diabetes mellitus	1.33	4.60e-1	38/43 (88.37%)	HSPD1;HLA-DQA1;GAD1;...
Ribosome	1.31	4.85e-1	113/158 (71.52%)	RPL36AL;RPS26;RPL13;...
Collecting duct acid secretion	1.31	4.72e-1	22/27 (81.48%)	CA2;SLC4A1;ATP6V1B1;...
Pancreatic secretion	1.31	4.63e-1	87/102 (85.29%)	CA2;ITPR1;GNAS;...
Cushing syndrome	1.30	4.67e-1	125/155 (80.65%)	PBX1;STAR;ITPR1;...
Synaptic vesicle cycle	-1.27	3.53e-1	63/78 (80.77%)	SLC6A1;ATP6V0B;SLC6A7;...
IL-17 signaling pathway	-1.27	3.57e-1	84/94 (89.36%)	CSF2;IKBKE;CCL20;...
mTOR signaling pathway	-1.27	3.56e-1	114/154 (74.03%)	MAPK1;ATP6V1D;NPRL2;...
Glycerolipid metabolism	-1.27	3.64e-1	44/61 (72.13%)	DGKD;AKR1A1;LPIN2;...
SNARE interactions in vesicular transport	-1.27	3.60e-1	19/33 (57.58%)	STX4;STX16;BNIP1;...
Cytosolic DNA-sensing pathway	-1.29	3.63e-1	52/63 (82.54%)	CXCL10;POLR2L;POLR3B;...
Regulation of lipolysis in adipocytes	-1.31	3.45e-1	52/55 (94.55%)	NPY1R;ADCY7;AKT1;...
Glycerophospholipid metabolism	-1.31	3.55e-1	71/98 (72.45%)	PEMT;PISD;PLAAT3;...
Phagosome	-1.31	3.63e-1	118/152 (77.63%)	FCGR2B;ATP6V0A1;FCGR2A;...
Metabolism of xenobiotics by cytochrome P450	-1.39	3.16e-1	49/77 (63.64%)	HSD11B1;CYP2E1;GSTA4;...
Viral protein interaction with cytokine and cytokine re...	-1.40	3.23e-1	84/100 (84%)	TNFRSF14;IL10RA;CCL18;...
Arginine biosynthesis	-1.42	2.73e-1	17/22 (77.27%)	ARG2;GLS;ASS1
JAK-STAT signaling pathway	-1.44	2.63e-1	146/162 (90.12%)	IL2RA;CREBBP;PDGFRB;...
Cytokine-cytokine receptor interaction	-1.44	2.78e-1	246/295 (83.39%)	NGFR;CXCL8;IL18;...
Steroid hormone biosynthesis	-1.47	2.22e-1	43/61 (70.49%)	CYP3A7;HSD17B8;CYP7A1;...
Nicotinate and nicotinamide metabolism	-1.47	2.37e-1	25/35 (71.43%)	ENPP1;NT5C;CD38;...
Lysosome	-1.47	2.49e-1	115/128 (89.84%)	IDS;AP1B1;SMPD1;...
Complement and coagulation cascades	-1.48	2.53e-1	76/85 (89.41%)	KLKB1;THBD;F12;...
Arachidonic acid metabolism	-1.48	2.66e-1	48/61 (78.69%)	PTGIS;PLA2G4C;ALOX12;...
Amino sugar and nucleotide sugar metabolism	-1.52	2.17e-1	38/48 (79.17%)	PMM2;GALT;PMM1;...
Ascorbate and aldarate metabolism	-1.54	2.03e-1	15/30 (50%)	GUSB;AKR1A1;UGT2B4;...
Staphylococcus aureus infection	-1.55	2.10e-1	72/95 (75.79%)	FPR3;DSG1;HLA-DQB1;...
Autophagy	-1.56	2.14e-1	113/169 (66.86%)	RB1CC1;ATG2A;ATG101;...
Rheumatoid arthritis	-1.60	1.70e-1	78/93 (83.87%)	CXCL8;IL18;CXCL6;...
Estrogen signaling pathway	-1.63	1.57e-1	119/137 (86.86%)	SOS1;KRT23;MAP2K2;...
Malaria	-1.69	9.91e-2	44/50 (88%)	TLR2;SDC1;LRP1;...
Pertussis	-1.69	1.14e-1	64/76 (84.21%)	CD14;LY96;C1QB;...
Sulfur metabolism	-1.73	1.16e-1	9/10 (90%)	TST;MPST;PAPSS1;...
Selenocompound metabolism	-1.81	8.42e-2	11/17 (64.71%)	SCLY;PAPSS1;CTH;...
Pantothenate and CoA biosynthesis	-1.86	9.91e-2	14/21 (66.67%)	ENPP1;PANK3;BCAT1;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	4uM	6H	Hide ▲

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H	Hide ▲
MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H	Show ▼

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	10uM	72H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H, 24H	Show ▼

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.01uM - 10uM	24H	Show ▼

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Umbilical vein

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HUVEC-C	CVCL_2959	Homo sapiens	0.04uM - 3.33uM	24H	Show ▼